Skip to content
10-Q

Quarterly Report

VITRO BIOPHARMA, INC.

0001641172-25-015758

← back to feed
Filed
Jun 20, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Jun 20, 2025 4.46M sh
Long Term Debt Q2 2025 · Apr 30, 2025 $1.12M
Long Term Debt Q2 2025 · Oct 31, 2024 $3.05M
Short Term Debt Q2 2025 · Apr 30, 2025 $3.48M
Short Term Debt Q2 2025 · Oct 31, 2024 $5.2M
Current Liabilities Q2 2025 · Apr 30, 2025 $13.9M
Current Liabilities Q2 2025 · Oct 31, 2024 $10.06M
Total Liabilities Q2 2025 · Apr 30, 2025 $15.64M
Total Liabilities Q2 2025 · Oct 31, 2024 $14.09M
Current Assets Q2 2025 · Apr 30, 2025 $597.32K
Current Assets Q2 2025 · Oct 31, 2024 $975.75K
Total Assets Q2 2025 · Apr 30, 2025 $4.58M
Total Assets Q2 2025 · Oct 31, 2024 $5.09M
Shares Diluted Q2 2025 · Apr 30, 2024 4.46M sh
Shares Diluted Q2 2025 · Apr 30, 2024 4.46M sh
Operating Cash Flow Q2 2025 · Apr 30, 2024 −$1.73M
Stockholders Equity Q2 2025 · Apr 30, 2024 −$7.56M
Stockholders Equity Q2 2025 · Jan 31, 2024 −$4.83M
Stockholders Equity Q2 2025 · Oct 31, 2023 −$1.09M
Eps Diluted Q2 2025 · Apr 30, 2024 −$0.70
Eps Diluted Q2 2025 · Apr 30, 2024 −$1.72
Eps Basic Q2 2025 · Apr 30, 2024 −$0.70
Eps Basic Q2 2025 · Apr 30, 2024 −$1.72
Sga Expense Q2 2025 · Apr 30, 2024 $1.28M
Sga Expense Q2 2025 · Apr 30, 2024 $3.69M
Rd Expense Q2 2025 · Apr 30, 2024 $139.69K
Rd Expense Q2 2025 · Apr 30, 2024 $295.92K
Net Income Q2 2025 · Apr 30, 2024 −$3.12M
Net Income Q2 2025 · Apr 30, 2024 −$7.69M
Net Income Q2 2025 · Jan 31, 2024 −$4.57M
Operating Income Q2 2025 · Apr 30, 2024 −$945.75K
Operating Income Q2 2025 · Apr 30, 2024 −$5.82M
Gross Profit Q2 2025 · Apr 30, 2024 $478.77K
Gross Profit Q2 2025 · Apr 30, 2024 $817.78K
Cost Of Revenue Q2 2025 · Apr 30, 2024 $94.17K
Cost Of Revenue Q2 2025 · Apr 30, 2024 $179.36K
Revenue Q2 2025 · Apr 30, 2024 $572.94K
Revenue Q2 2025 · Apr 30, 2024 $997.15K